&w=3840&q=100)
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing.
"At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said.
Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients".
Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said.
It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Stricter shelf life rule a bitter pill to swallow for pharma companies
A new rule by the drug regulator barring exports of any product with less than 60% shelf life is causing huge losses to the domestic pharmaceutical industry with manufacturers being forced to destroy stocks to comply. In a recent meeting with the Central Drugs Standard Control Organisation ( CDSCO ), the industry urged for a revision in the rule or an alternative solution. Pharma lobby group Federation of Pharma Entrepreneurs ( FOPE ) has also written to the regulator this week urging the latter to repeal the rule introduced last year. "Our view is that if the importing country allows it, why should we have an objection," said Harish Jain, president, FOPE. "This is causing substantial losses due to destruction of stock," FOPE said in its letter, a copy of which was seen by ET. Live Events "If the manufacturing date is August 2025 and the expiry is July 2027, the drug regulatory authority wants at the time of exports the consignment should have 60% minimum shelf life remaining. Otherwise, they will not allow export," said a senior industry executive. The CDSCO has updated the export NOC checklist , making regulatory approval mandatory for all medicines destined for exports after reports that an Indian company had been exporting unlicensed combinations of drugs to African nations like Ghana and Nigeria. "We have requested the regulatory authority to make this rule mandatory for narcotic drugs, opioid drug combinations, and other habit forming drugs but not for every medicine, even vitamins," said a second industry executive. "This has become a huge challenge for the industry. The companies have to destroy stocks because the export consignments are custom-made with importing country details and cannot be used in India." A government official said the step was taken to make sure that such incidents do not occur. "India is a world pharmacy and we cannot afford to face reputational challenges, particularly concerning the quality of drugs which are being exported to other countries," he said.
Time of India
a day ago
- Time of India
Popping acidity pills? The quick fix may have a hidden cost
Ranitidine, a once-trusted over-the-counter anti-acidity pill taken by millions, is under scrutiny after fears that it may contain a probable cancer-causing contaminant. The Central Drugs Standard Control Organisation (CDSCO) has asked states to direct manufacturers to monitor NDMA levels in the drug. Durgesh Nandan Jha speaks to Dr Ashwini Kumar Setya, senior gastroenterologist at Medanta Hospital , to assess the risks Why has this pill become so controversial? Ranitidine belongs to a class of drugs called histamine-2 (H-2) blockers, which reduce but don't completely stop stomach acid production. Ranitidine is not carcinogenic on its own. The concern arises when the molecule breaks down over time or under certain conditions to form N-Nitrosodimethylamine (NDMA), a nitrosamine linked to possible cancer risk. Since it's cheap and easily available, contamination could impact many. Sold under brand names like Zantac and Rantac, should we stop using Ranitidine? Should long-term users be concerned? We are yet to come across a medicine, including vitamins, which doesn't have side effects. No drug should be taken without medical supervision. Reports say the concentration of contaminants in Ranitidine is very small. But prolonged consumption and cumulative exposure could exceed safe limits. The Drugs Technical Advisory Board has suggested that drug makers reduce Ranitidine's shelf life to lower NDMA levels. Will that help? Ranitidine can degrade over time, especially when exposed to heat, humidity, and light, producing increased NDMA levels and potentially raising cancer risk. Reducing shelf life shortens the window in which NDMA can pile up, helping to keep it within safe limits. In 2020, the US FDA had raised similar concerns and ordered its withdrawal. Why is India still allowing manufacture and sale? CDSCO and the Drugs Controller General of India have been monitoring Ranitidine after the FDA and European Medicines Agency raised a red flag. An expert committee identified cancer risks, but there aren't any documented cases of cancer attributed to the drug in India. Pantoprazole (brand name Pan D) is another common anti-acidity pill. Any risks of misuse? Stomach acid serves three purposes — killing ingested germs, starting protein digestion, and activating pepsin for further protein breakdown. Drugs like Pantoprazole reduce stomach acid to nil, removing the first line of defence and raising chances of infections such as Hepatitis A and E, gastroenteritis, and typhoid. These drugs can also lead to bloating as the undigested food ferments in the gut, producing more gas. Which one's the safest acidity drug? And when to see a doctor instead of self-medicating? Short-term use of Ranitidine (up to two months) is not a likely cause for concern. But if considering long-term, talk to the doctor about switching to another H-2 blocker like Famotidine or a proton pump inhibitor (PPI) like Omeprazole. If you're using it just to relieve burning in the chest or upper abdomen, replace with a liquid antacid. Heartburn, acidity are now common due to sedentary lifestyle and poor diet. Any long-term effects of anti-acidity pills such as rebound acidity, peptic ulcers or even cancer? Since acid secretion becomes nil with Pantoprazole and other PPIs, the body responds by increasing the hormone gastrin, which makes glands that secrete acid proliferate. When you stop using the drug, those glands start secreting acid with a vengeance, causing rebound acidity. It's a vicious cycle that makes patients want to go back to the drug. One long-term effect of these pills is non-cancerous stomach polyps.
Business Standard
2 days ago
- Business Standard
Glenmark Pharma's US arm to launch Micafungin injection in the US market
Glenmark Pharmaceuticals announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, will launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), in the U.S. market this September. The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million. Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Marc Kikuchi, president & business head, North America said, We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need. Glenmarks Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication listed in Glenmarks approved label. All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmarks product is only approved for the indications listed in Glenmarks approved label and is not marketed for all RLD indications. IQVIA National Sales Perspectives: Retail & Non-Retail, June 2025. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip declined 1.38% to Rs 1,947.10 on the BSE.
